SCHEMBL8450332

SCHEMBL8450332

O=c1[nH][nH]c(=O)c2nc3ccccc3cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.46
RXFP1 Q9HBX9 1/20 0.46
ALDH1A1 P00352 4/20 0.45
GLA P06280 3/20 0.45
HPGD P15428 3/20 0.45
MAPT P10636 3/20 0.45
ACHE P22303 1/20 0.45
PDE2A O00408 2/20 0.42
PDE3B Q13370 2/20 0.42
PDE3A Q14432 2/20 0.42
RAB9A P51151 5/20 0.42
GAA P10253 3/20 0.42
NPC1 O15118 3/20 0.42
KMT2A Q03164 3/20 0.42
LMNA P02545 1/20 0.42
POLB P06746 1/20 0.42
PTBP1 P26599 1/20 0.42
RCE1 Q9Y256 1/20 0.42
USP2 O75604 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Choline SCHEMBL7503118 0.83 KDM4E (0.38) KDM4ERXFP1ALDH1A1GLAHPGD
SCHEMBL22717090 0.81 PDE2A (0.50) KDM4ERXFP1ALDH1A1GLAHPGD
SCHEMBL8572137 0.77 RXFP1 (0.50) KDM4ERXFP1ALDH1A1MAPTGAA
SCHEMBL6688762 0.77 DAO (0.47) KDM4ERXFP1ALDH1A1MAPTPDE3B
SCHEMBL633820 0.76 PARP1 (0.53) KDM4EALDH1A1PDE2APDE3BPDE3A
SCHEMBL26749714 0.75 ALDH1A1 (0.62) KDM4ERXFP1ALDH1A1GLAHPGD
SCHEMBL31572200 0.75 GRIN2D (0.52) KDM4EALDH1A1GLAHPGDMAPT
SCHEMBL11200843 0.75 GRIN2D (0.52) KDM4EALDH1A1GLAHPGDMAPT
SCHEMBL7547477 0.75 KDM4E (0.44) KDM4ERXFP1ALDH1A1GLAHPGD
SCHEMBL14820025 0.74 TYMS (0.44) KDM4ERXFP1ALDH1A1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0939757-A1 NOVEL INTEGRIN RECEPTOR ANTAGONISTS Dupont Pharmaceuticals Company (US) 1999-09-08 EP disclosed
EP-0931081-A1 PYRIDAZINO 4,5-B]-QUINOLINE 5-OXIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS GLYCINE ANTAGONISTS MERZ + CO. GmbH & Co. (DE) 1999-07-28 EP disclosed
US-5739133-A N-ACYLATED AND ALKYLATED DERIVATIVES OF PYRIDAZINO(4,5-B)-QUINOLINES; EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS; STROKES; ANTIISCHEMIC AND HYPOGLYCEMIC AGENTS; PSYCHOSIS; NEUROGODEGENERATIVE DISORDERS ZENECA LIMITED (GB) 1998-04-14 US disclosed
US-5733910-A Pyridazinedione compounds useful in the treating neurological disorders IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1998-03-31 US disclosed
WO-1998004556-A1 PYRIDAZINO [4,5-B]-QUINOLINE 5-OXIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS GLYCINE ANTAGONISTS MERZ + CO. GMBH & CO. (DE) 1998-02-05 WO disclosed
WO-1997023480-A1 NOVEL INTEGRIN RECEPTOR ANTAGONISTS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1997-07-03 WO disclosed
US-5604227-A EXCITATORY AMINO ACID ANTAGONIST; MONO, DI OR TRI-ACETYLATION OR ALKYLATION IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1997-02-18 US disclosed
US-5599814-A SUBSTITUTED PYRIDAZINO(4,5-B)QUINOLINES AS ANTAGONISTS OF EXCITATORY AMINO ACIDS IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) 1997-02-04 US disclosed
EP-0516297-B1 Pyridazinediones and their use in the treatment of neurological disorders ZENECA LTD (GB) 1996-10-30 EP disclosed
EP-0516297-A1 Pyridazinediones and their use in the treatment of neurological disorders ZENECA LIMITED (GB) 1992-12-02 EP disclosed